<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="183448">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00706121</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000593329</org_study_id>
    <secondary_id>S0000D</secondary_id>
    <secondary_id>U10CA037429</secondary_id>
    <nct_id>NCT00706121</nct_id>
  </id_info>
  <brief_title>S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000</brief_title>
  <acronym>ACP</acronym>
  <official_title>S0000D: A Study of the Effect of Vitamin E and/or Selenium on Adenomatous Colorectal Polyps (ACP) in Participants Enrolled in SELECT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying tissue samples in the laboratory from participants receiving treatment
      on the Selenium and Vitamin E Cancer Prevention Trial (SELECT) SWOG-S0000 may help doctors
      predict a participant's response to treatment and help plan the best treatment.

      PURPOSE: This phase III trial is studying the effect of vitamin E and/or selenium on
      colorectal polyps in men enrolled on SELECT Trial SWOG-S0000.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To assess the effect of selenium on colorectal adenoma (CRA) occurrence.

        -  To assess the effect of selenium on number, location, size, histologic type, and degree
           of dysplasia of CRA.

        -  To assess the effect of selenium on colorectal cancer (CRC) incidence.

      Secondary

        -  To assess the effect of vitamin E on CRA occurrence.

        -  To assess the effect of vitamin E on CRC incidence.

      Tertiary

        -  To explore the effect modification of selenium and vitamin E by aspirin on CRA
           occurrence.

        -  To explore the effect modification of selenium and vitamin E by body mass index.

      OUTLINE: This is a multicenter study.

      Endoscopically obtained tissue samples are reviewed by study pathologists to confirm the
      presence (or absence) of a colorectal adenoma (CRA). If a CRA is present, the number,
      location, size, histology, and degree of dysplasia are documented. The CRA is also reviewed
      to exclude a diagnosis of colorectal cancer.

      Additional data, including aspirin use, height and weight, date of birth, and other
      demographic and baseline characteristics, is also obtained. Participants' medical records
      are reviewed periodically.

      Participants are followed annually.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Selenium on Colorectal Adenoma (CRA) Occurrence</measure>
    <time_frame>Occurence of a colorectal procedure in which CRA could be evaluated is collected every 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Selenium on Advanced Neoplasia</measure>
    <time_frame>Occurence of a colorectal procedure in which CRA or CRC could be evaluated is collected every 6 months</time_frame>
    <description>Adenomas with diameter &gt;=1cm or any adenoma with villous features or high-grade dysplasia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Selenium and/or Vitamin E on Colorectal Cancer (CRC) Incidence</measure>
    <time_frame>Occurence of a colorectal procedure in which CRC could be evaluated is collected every 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Selenium on Occurrences of Multiple (&gt;2) Adenomas</measure>
    <time_frame>Occurence of a colorectal procedure in which CRA could be evaluated is collected every 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Vitamin E on CRA Occurrence</measure>
    <time_frame>Occurence of a colorectal procedure in which CRA could be evaluated is collected every 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Effect Modification of Selenium by Body Mass Index on CRA Occurrence</measure>
    <time_frame>Occurence of a colorectal procedure in which CRA or CRC could be evaluated is collected every 6 months. BMI is collected annually.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effect Modification of Selenium by Aspirin on CRA Occurrence</measure>
    <time_frame>Occurence of a colorectal procedure in which CRA or CRC could be evaluated and aspirin use is collected every 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effect Modification of Vitamin E by Body Mass Index on CRA Occurence</measure>
    <time_frame>Occurence of a colorectal procedure in which CRA or CRC could be evaluated and aspirin use is collected every 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effect Modification of Vitamin E by Aspirin on CRA Occurrence</measure>
    <time_frame>Occurence of a colorectal procedure in which CRA or CRC could be evaluated and aspirin use is collected every 6 months</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">8097</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Vitamin E + selenium placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin E and selenium placebo daily for 7 - 12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium + vitamin E placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selenium and vitamin E placebo daily for 7 - 12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin E + selenium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin E and selenium daily for 7 - 12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin E placebo + selenium placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vitamin E placebo and selenium placebo daily for 7 - 12 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E</intervention_name>
    <description>400 IU daily by mouth for 7 - 12 years</description>
    <arm_group_label>Vitamin E + selenium placebo</arm_group_label>
    <arm_group_label>Vitamin E + selenium</arm_group_label>
    <other_name>alpha tocopherol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selenium</intervention_name>
    <description>200 mcg daily for 7 - 12 years</description>
    <arm_group_label>Selenium + vitamin E placebo</arm_group_label>
    <arm_group_label>Vitamin E + selenium</arm_group_label>
    <other_name>L-selenomethionine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E placebo</intervention_name>
    <description>1 pill by mouth daily for 7 - 12 years</description>
    <arm_group_label>Selenium + vitamin E placebo</arm_group_label>
    <arm_group_label>Vitamin E placebo + selenium placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selenium placebo</intervention_name>
    <description>1 pill by mouth daily for 7 - 12 years</description>
    <arm_group_label>Vitamin E + selenium placebo</arm_group_label>
    <arm_group_label>Vitamin E placebo + selenium placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Enrolled on the Selenium and Vitamin E Cancer Prevention Trial (SELECT) SWOG-S0000

          -  Screened by lower endoscopy (i.e., sigmoidoscopy and/or colonoscopy) after
             randomization on SELECT trial

        PATIENT CHARACTERISTICS:

          -  Willing to sign an applicable medical records release form

          -  Willing to allow the release of tissue for central pathology review of resected
             polyps and endoscopic biopsies

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Peter Lance, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>86724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 15, 2017</lastchanged_date>
  <firstreceived_date>June 26, 2008</firstreceived_date>
  <firstreceived_results_date>February 15, 2017</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>adenomatous polyp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://swog.org/Visitors/Download/Policies/Policy43.pdf</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin E + Selenium Placebo</title>
          <description>Vitamin E and selenium placebo daily for 7 - 12 years
Vitamin E: 400 IU daily by mouth for 7 - 12 years
selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
        <group group_id="P2">
          <title>Selenium + Vitamin E Placebo</title>
          <description>Selenium and vitamin E placebo daily for 7 - 12 years
Selenium: 200 mcg daily for 7 - 12 years
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
        <group group_id="P3">
          <title>Vitamin E + Selenium</title>
          <description>Vitamin E and selenium daily for 7 - 12 years
Vitamin E: 400 IU daily by mouth for 7 - 12 years
Selenium: 200 mcg daily for 7 - 12 years</description>
        </group>
        <group group_id="P4">
          <title>Vitamin E Placebo + Selenium Placebo</title>
          <description>Vitamin E placebo and selenium placebo daily for 7 - 12 years
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years
selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2039"/>
                <participants group_id="P2" count="2096"/>
                <participants group_id="P3" count="2030"/>
                <participants group_id="P4" count="1929"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1643"/>
                <participants group_id="P2" count="1700"/>
                <participants group_id="P3" count="1626"/>
                <participants group_id="P4" count="1577"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="396"/>
                <participants group_id="P2" count="396"/>
                <participants group_id="P3" count="404"/>
                <participants group_id="P4" count="352"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin E + Selenium Placebo</title>
          <description>Vitamin E and selenium placebo daily for 7 - 12 years
Vitamin E: 400 IU daily by mouth for 7 - 12 years
selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
        <group group_id="B2">
          <title>Selenium + Vitamin E Placebo</title>
          <description>Selenium and vitamin E placebo daily for 7 - 12 years
Selenium: 200 mcg daily for 7 - 12 years
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
        <group group_id="B3">
          <title>Vitamin E + Selenium</title>
          <description>Vitamin E and selenium daily for 7 - 12 years
Vitamin E: 400 IU daily by mouth for 7 - 12 years
Selenium: 200 mcg daily for 7 - 12 years</description>
        </group>
        <group group_id="B4">
          <title>Vitamin E Placebo + Selenium Placebo</title>
          <description>Vitamin E placebo and selenium placebo daily for 7 - 12 years
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years
selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1643"/>
            <count group_id="B2" value="1700"/>
            <count group_id="B3" value="1626"/>
            <count group_id="B4" value="1577"/>
            <count group_id="B5" value="6546"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="58" upper_limit="66"/>
                    <measurement group_id="B2" value="62" lower_limit="58" upper_limit="66"/>
                    <measurement group_id="B3" value="62" lower_limit="58" upper_limit="67"/>
                    <measurement group_id="B4" value="62" lower_limit="58" upper_limit="67"/>
                    <measurement group_id="B5" value="62" lower_limit="58" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Number of males</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1643"/>
                    <measurement group_id="B2" value="1700"/>
                    <measurement group_id="B3" value="1626"/>
                    <measurement group_id="B4" value="1577"/>
                    <measurement group_id="B5" value="6546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Colon polyps</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="355"/>
                    <measurement group_id="B2" value="347"/>
                    <measurement group_id="B3" value="339"/>
                    <measurement group_id="B4" value="355"/>
                    <measurement group_id="B5" value="1396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Selenium on Colorectal Adenoma (CRA) Occurrence</title>
        <time_frame>Occurence of a colorectal procedure in which CRA could be evaluated is collected every 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Selenium</title>
            <description>Active Selenium +/- Vitamin E</description>
          </group>
          <group group_id="O2">
            <title>Selenium Placebo</title>
            <description>Selenium Placebo +/- Vitamin E</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Selenium on Colorectal Adenoma (CRA) Occurrence</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3326"/>
                <count group_id="O2" value="3220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1136"/>
                    <measurement group_id="O2" value="1150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Log binomial regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Selenium on Advanced Neoplasia</title>
        <description>Adenomas with diameter &gt;=1cm or any adenoma with villous features or high-grade dysplasia</description>
        <time_frame>Occurence of a colorectal procedure in which CRA or CRC could be evaluated is collected every 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Selenium</title>
            <description>Active selenium +/- Vitamin E</description>
          </group>
          <group group_id="O2">
            <title>Selenium Placebo</title>
            <description>Selenium placebo +/- Vitamin E</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Selenium on Advanced Neoplasia</title>
          <description>Adenomas with diameter &gt;=1cm or any adenoma with villous features or high-grade dysplasia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3326"/>
                <count group_id="O2" value="3220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="269"/>
                    <measurement group_id="O2" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Log binomial regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Selenium and/or Vitamin E on Colorectal Cancer (CRC) Incidence</title>
        <time_frame>Occurence of a colorectal procedure in which CRC could be evaluated is collected every 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin E</title>
            <description>Vitamin E + matching placebo for selenium</description>
          </group>
          <group group_id="O2">
            <title>Selenium</title>
            <description>Selenium + matching placebo for vitamin E</description>
          </group>
          <group group_id="O3">
            <title>Combination</title>
            <description>Vitamin E + selenium</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo for vitamin E + matching placebo for selenium</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Selenium and/or Vitamin E on Colorectal Cancer (CRC) Incidence</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1643"/>
                <count group_id="O2" value="1700"/>
                <count group_id="O3" value="1626"/>
                <count group_id="O4" value="1577"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effect of Selenium on Occurrences of Multiple (&gt;2) Adenomas</title>
        <time_frame>Occurence of a colorectal procedure in which CRA could be evaluated is collected every 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Selenium</title>
            <description>Active selenium +/- vitamin E</description>
          </group>
          <group group_id="O2">
            <title>Selenium Placebo</title>
            <description>Selenium placebo +/- vitamin E</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Selenium on Occurrences of Multiple (&gt;2) Adenomas</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3326"/>
                <count group_id="O2" value="3220"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Log binomial regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Vitamin E on CRA Occurrence</title>
        <time_frame>Occurence of a colorectal procedure in which CRA could be evaluated is collected every 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin E</title>
            <description>Active vitamin E +/- selenium</description>
          </group>
          <group group_id="O2">
            <title>Vitamin E Placebo</title>
            <description>Vitamin E placebo +/- selenium</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Vitamin E on CRA Occurrence</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3269"/>
                <count group_id="O2" value="3277"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1159"/>
                    <measurement group_id="O2" value="1127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Log binomial regression</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effect Modification of Selenium by Body Mass Index on CRA Occurrence</title>
        <time_frame>Occurence of a colorectal procedure in which CRA or CRC could be evaluated is collected every 6 months. BMI is collected annually.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Selenium</title>
            <description>Active selenium +/- vitamin E</description>
          </group>
          <group group_id="O2">
            <title>Selenium Placebo</title>
            <description>Selenium placebo +/- vitamin E</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Modification of Selenium by Body Mass Index on CRA Occurrence</title>
          <units>percentage with CRA in subgroup</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1133"/>
                <count group_id="O2" value="1146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overweight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2"/>
                    <measurement group_id="O2" value="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.2"/>
                    <measurement group_id="O2" value="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effect Modification of Selenium by Aspirin on CRA Occurrence</title>
        <time_frame>Occurence of a colorectal procedure in which CRA or CRC could be evaluated and aspirin use is collected every 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Selenium</title>
            <description>Active selenium +/- vitamin E</description>
          </group>
          <group group_id="O2">
            <title>Selenium Placebo</title>
            <description>Selenium placebo +/- vitamin E</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Modification of Selenium by Aspirin on CRA Occurrence</title>
          <units>ercentage with CRA in subgroup</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1136"/>
                <count group_id="O2" value="1150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Users</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5"/>
                    <measurement group_id="O2" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-users</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.9"/>
                    <measurement group_id="O2" value="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effect Modification of Vitamin E by Body Mass Index on CRA Occurence</title>
        <time_frame>Occurence of a colorectal procedure in which CRA or CRC could be evaluated and aspirin use is collected every 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin E</title>
            <description>Active vitamin E +/- selenium</description>
          </group>
          <group group_id="O2">
            <title>Vitamin E Placebo</title>
            <description>Vitamin E placebo +/- selenium</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Modification of Vitamin E by Body Mass Index on CRA Occurence</title>
          <units>ercentage with CRA in subgroup</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1155"/>
                <count group_id="O2" value="1124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overweight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5"/>
                    <measurement group_id="O2" value="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effect Modification of Vitamin E by Aspirin on CRA Occurrence</title>
        <time_frame>Occurence of a colorectal procedure in which CRA or CRC could be evaluated and aspirin use is collected every 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Vitamin E</title>
            <description>Active vitamin E +/- selenium</description>
          </group>
          <group group_id="O2">
            <title>Vitamin E Placebo</title>
            <description>Vitamin E placebo +/- selenium</description>
          </group>
        </group_list>
        <measure>
          <title>Effect Modification of Vitamin E by Aspirin on CRA Occurrence</title>
          <units>ercentage with CRA in subgroup</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1159"/>
                <count group_id="O2" value="1127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Users</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-users</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Every 6 months while the participant is receiving study supplements.</time_frame>
      <desc>There are no Adverse Events (AE) associated with this trial. All AEs were reported for the parent trial (SELECT - S0000). Included below are the AEs for the participants on this trial that were included in the primary analysis. These AEs were also reported for the parent trial.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vitamin E + Selenium Placebo</title>
          <description>Vitamin E and selenium placebo daily for 7 - 12 years
Vitamin E: 400 IU daily by mouth for 7 - 12 years
selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
        <group group_id="E2">
          <title>Selenium + Vitamin E Placebo</title>
          <description>Selenium and vitamin E placebo daily for 7 - 12 years
Selenium: 200 mcg daily for 7 - 12 years
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
        <group group_id="E3">
          <title>Vitamin E + Selenium</title>
          <description>Vitamin E and selenium daily for 7 - 12 years
Vitamin E: 400 IU daily by mouth for 7 - 12 years
Selenium: 200 mcg daily for 7 - 12 years</description>
        </group>
        <group group_id="E4">
          <title>Vitamin E Placebo + Selenium Placebo</title>
          <description>Vitamin E placebo and selenium placebo daily for 7 - 12 years
Vitamin E placebo: 1 pill by mouth daily for 7 - 12 years
selenium placebo: 1 pill by mouth daily for 7 - 12 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="1577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1577"/>
              </event>
              <event>
                <sub_title>Cardiovascular-other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1577"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1577"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Surgery-hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1577"/>
              </event>
              <event>
                <sub_title>Cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile impotence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1577"/>
              </event>
              <event>
                <sub_title>Peripheral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1577"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1577"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="100" subjects_at_risk="1577"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="1643"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="1700"/>
                <counts group_id="E3" subjects_affected="112" subjects_at_risk="1626"/>
                <counts group_id="E4" subjects_affected="100" subjects_at_risk="1577"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>SELECT/S0000D Statistician</name_or_title>
      <organization>SWOG Statistical Center</organization>
      <phone>206-667-4623</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
